• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Mitosol Logo

Mitosol®

Mitosol Has It All

  • HOME
  • CONTACT
  • ORDER
  • RESOURCES
    • Mitosol Resource Center
    • The Mitosol Kit
    • What is Mitosol?
    • Getting Started with Mitosol
  • ABOUT US

About Us

Mobius Therapeutics™ vision is to lead in ophthalmic perioperative pharmaceuticals.  Our mission is to identify challenging needs and innovate solutions to improve patient care, patient access, and provider safety.

MITOSOLVED.™ 

Glaucoma surgery is done in a highly regulated environment and new USP <800> standards bring more vigilance to the usage and disposal of hazardous drugs, like mitomycin C, in the ophthalmic surgical arena.  Additionally, glaucoma surgery requires supplies to be state of the art, reliable, and readily available, so that the surgical suite can run like a well-oiled machine.

Fortunately, MITOSOL has it all. 

Mobius Therapeutics™ offers the first and only FDA-approved ophthalmic formulation of MMC.  Mitosol (mitomycin for solution) Kit for Ophthalmic Use is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.  It can be stored at room temperature for up to 24 months, is ready on demand and is reconstituted in a closed system that’s USP <800> compliant.  In short, MITOSOL has created a new standard of care in glaucoma surgery.

Visit www.MobiusTherapeutics.com to learn more about our perioperative pharmaceutical franchise and our mission to improve the convenience, safety and integrity of perioperative pharmaceuticals for ophthalmic applications.

Mobius Therapeutics™, LLC 
www.mobiustherapeutics.com    
1-877-393-6486

WMI-023 Rev 11/2019

Footer

INDICATION

Mitosol® (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic Use is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.

Dosage & Administration

Mitosol® is intended for topical application to the surgical site of glaucoma filtration surgery and must be reconstituted prior to application. Sponges provided within the Mitosol® kit should be fully saturated with the entire reconstituted contents in a manner prescribed in the Instructions For Use. The sponge(s) should be applied to the treatment area for two minutes. Reconstituted Mitosol® should be used within one hour of reconstitution.

US Patents #7,806,265, #8,186,511, #D685,962, #D685,963, #9,205,075, #9,539,241 and #9,649,428; other international patents issued and pending.

Product Information

Please click here for full Product Information for Mitosol®

IMPORTANT SAFETY INFORMATION
Contraindications

Mitosol® is contraindicated in patients that have demonstrated a hypersensitivity to mitomycin in the past.

Warnings & Precautions

Cell Death: Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or sclera damage including thinning or perforation. Direct contact with the corneal endothelium will result in cell death. Hypotony: The use of mitomycin has been associated with an increased instance of post-operative hypotony. Cataract Development: Use in phakic patients has been correlated to a higher instance of lenticular change and cataract formation. Embryo-Fetal Toxicity: Can cause fetal harm. Advise of potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to use.

Adverse Events & Reactions

The most frequent adverse reactions to Mitosol® occur locally and include hypotony, hypotony maculopathy, blebitis, endophthalmitis, vascular reactions, corneal reactions, and cataract. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch, or call 1-800-FDA-1088.

This site is intended only for US residents.
Use of website is governed by the Terms of Use and Privacy Policy
Corporate Responsibility